Patents by Inventor Michell Hawkins
Michell Hawkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390888Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. in certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. in some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: GrantFiled: March 11, 2020Date of Patent: July 19, 2022Assignee: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Publication number: 20210347859Abstract: Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.Type: ApplicationFiled: May 6, 2021Publication date: November 11, 2021Inventors: Scott Simplot, Bradley M. Mitteness, Michelle Hawkins, Jason Hull, Brian Robley, Philip Larson, Michael Brielmaier, Benjamin Willaert, Vergene Harkins
-
Patent number: 11168127Abstract: Compositions are described that include colostrum and/or milk replacer combined with pathogen specific avian antibodies. These pathogen specific avian antibodies include antibodies against pathogens causing infections and disease in the digestive tract as well as outside the digestive tract. Feeding regimens and methods for administering the colostrum and/or milk replacer with the pathogen specific avian antibodies result in the presence of IgY antibodies in the serum of a neonatal animal. The IgY antibody in the serum can neutralize pathogens causing infections outside of the digestive tract.Type: GrantFiled: December 1, 2016Date of Patent: November 9, 2021Assignee: CAMAS INCORPORATEDInventors: Bradley M. Mitteness, Connie Phillips, Jason Hull, Michelle Hawkins, Ky McCraken
-
Patent number: 10626418Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: GrantFiled: July 24, 2018Date of Patent: April 21, 2020Assignee: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Publication number: 20190017074Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: ApplicationFiled: July 24, 2018Publication date: January 17, 2019Applicant: Amyris, Inc.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 10041092Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: GrantFiled: September 9, 2016Date of Patent: August 7, 2018Assignee: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 9914941Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: GrantFiled: September 2, 2014Date of Patent: March 13, 2018Assignee: AMYRIS, INC.Inventors: Timothy Stevens Gardner, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Publication number: 20170058299Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: ApplicationFiled: September 9, 2016Publication date: March 2, 2017Applicant: Amyris, Inc.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 9476065Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: GrantFiled: December 19, 2014Date of Patent: October 25, 2016Assignee: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 9410214Abstract: Provided herein are compositions and methods for improved production of acetyl-CoA and acetyl-CoA derived compounds in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a phosphoketolase (PK), and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a phosphotransacetylase (PTA). In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase. In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2. The compositions and methods described herein provide an efficient route for the heterologous production of acetyl-CoA-derived compounds, including but not limited to, isoprenoids, polyketides, and fatty acids.Type: GrantFiled: March 14, 2014Date of Patent: August 9, 2016Assignee: Amyris, Inc.Inventors: Kristy Michelle Hawkins, Tina Tipawan Mahatdejkul-Meadows, Adam Leon Meadows, Lauren Barbara Pickens, Anna Tai, Annie Ening Tsong
-
Publication number: 20150184199Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.Type: ApplicationFiled: December 19, 2014Publication date: July 2, 2015Applicant: AMYRIS, INC.Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
-
Patent number: 8859261Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: GrantFiled: October 24, 2013Date of Patent: October 14, 2014Assignee: Amyris, Inc.Inventors: Timothy Stevens Gardner, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Publication number: 20140273144Abstract: Provided herein are compositions and methods for improved production of acetyl-CoA and acetyl-CoA derived compounds in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a phosphoketolase (PK), and a functional disruption of an endogenous enzyme that converts acetyl phosphate to acetate. In some embodiments, the host cell further comprises a heterologous nucleotide sequence encoding a phosphotransacetylase (PTA). In some embodiments, the enzyme that converts acetyl phosphate to acetate is a glycerol-1-phosphatase. In some embodiments, the glycerol-1-phosphatase is GPP1/RHR2. In some embodiments, the glycerol-1-phosphatase is GPP2/HOR2. The compositions and methods described herein provide an efficient route for the heterologous production of acetyl-CoA-derived compounds, including but not limited to, isoprenoids, polyketides, and fatty acids.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventors: Kristy Michelle Hawkins, Tina Tipawan Mahatdejkul-Meadows, Adam Leon Meadows, Lauren Barbara Pickens, Anna Tai, Annie Ening Tsong
-
Publication number: 20140154765Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: ApplicationFiled: October 24, 2013Publication date: June 5, 2014Applicant: AMYRIS, INC.Inventors: Timothy Stevens GARDNER, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Publication number: 20140019309Abstract: An online virtual mall is a website, video game, or arcade that allows shoppers to shop and purchase items, as if they were in a real commercial mall. The online virtual mall contains more than two vendors or companies. The vendors or companies are obtained for the online virtual mall via affiliate programs, or individual contracts between the operators and developers of the website, video game or arcade, and the vendors or companies. Visitors will enter into the website, video game or arcade to shop and purchase product from individual vendors or companies. The vendors or companies will be responsible for billing and shipping of their products.Type: ApplicationFiled: July 16, 2012Publication date: January 16, 2014Inventor: Dana Michelle Hawkins
-
Publication number: 20140019556Abstract: A social media site where parents, guardians, caregivers and individuals of autism can interact with each other. The social media website can also provide articles and information regarding autism. The website can also provide books and other products that will provide entertainment, help and support.Type: ApplicationFiled: July 16, 2012Publication date: January 16, 2014Inventor: Dana Michelle Hawkins
-
Patent number: 8603800Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: GrantFiled: January 28, 2013Date of Patent: December 10, 2013Assignee: AMYRIS, Inc.Inventors: Timothy Stevens Gardner, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Patent number: 8415136Abstract: Provided herein are compositions and methods for the heterologous production of acetyl-CoA-derived isoprenoids in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an acetaldehyde dehydrogenase, acetylating (ADA, E.C. 1.2.1.10) and an MEV pathway comprising an NADH-using HMG-CoA reductase. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding an ADA and an MEV pathway comprising an acetoacetyl-CoA synthase. In some embodiments, the genetically modified host cell further comprises one or more heterologous nucleotide sequences encoding a phosphoketolase and a phosphotransacetylase. In some embodiments, the genetically modified host cell further comprises a functional disruption of the native PDH-bypass. The compositions and methods described herein provide an energy-efficient yet redox balanced route for the heterologous production of acetyl-CoA-derived isoprenoids.Type: GrantFiled: November 9, 2012Date of Patent: April 9, 2013Assignee: Amyris, Inc.Inventors: Timothy Stevens Gardner, Kristy Michelle Hawkins, Adam Leon Meadows, Annie Ening Tsong, Yoseph Tsegaye
-
Patent number: D672117Type: GrantFiled: May 7, 2012Date of Patent: December 11, 2012Inventors: William Hawkins, Michell Hawkins
-
Patent number: D695491Type: GrantFiled: February 4, 2013Date of Patent: December 17, 2013Inventors: Michell Hawkins, William Hampton Hawkins